What question did this study set out to answer?

The aim is to assess the predictive ability of microRNAs combined with clinical risk models for HCC recurrence post-liver transplantation.

February 28, 2026Scientific ReportsOpen Access

Combining tissue-derived microRNAs with clinical risk models for prediction of HCC recurrence after liver transplantation: A proof-of-concept study

View Full Paper

Ask AI

Bookmark

Authors

TLTheresa LedererOtto-von-Guericke University Magdeburg KLKonrad LehrKlinikum Magdeburg SBStefanie BobeGerman Cancer Research Center

Discussion

Member takes

Implication

This proof-of-concept study evaluates microRNAs to predict HCC recurrence in patients after liver transplantation, suggesting improved risk assessment.

Key Points

The aim is to assess the predictive ability of microRNAs combined with clinical risk models for HCC recurrence post-liver transplantation.
Retrospective analysis including 20 patients with HCC who underwent liver transplantation
MiRNA profiling on formalin-fixed, paraffin-embedded HCC tissue
Evaluation of miRNA expression in conjunction with clinical risk models
Kaplan-Meier analysis to assess recurrence-free survival
Identified a 3-miRNA signature (miR-3692-5p, miR-424, miR-718) that distinguishes between recurrence and non-recurrence
Increased area under the ROC curve from 0.7 to 0.94-0.96 with the addition of miRNA signature to clinical models
High-risk patients had a shorter median recurrence-free survival of 17 months compared to 38.5 months for low-risk patients, p < 0.05

Cite This Study

Lederer et al. (2026) studied this question.

synapsesocial.com/papers/69a288170a974eb0d3c04068 https://doi.org/10.1038/s41598-026-41688-9

View Full Paper

Ask AI

Bookmark

February 28, 2026Scientific ReportsOpen Access

Combining tissue-derived microRNAs with clinical risk models for prediction of HCC recurrence after liver transplantation: A proof-of-concept study

View Full Paper

Ask AI

Bookmark

Authors

TLTheresa LedererOtto-von-Guericke University Magdeburg KLKonrad LehrKlinikum Magdeburg SBStefanie BobeGerman Cancer Research Center

Discussion

Member takes

Implication

This proof-of-concept study evaluates microRNAs to predict HCC recurrence in patients after liver transplantation, suggesting improved risk assessment.

Key Points

The aim is to assess the predictive ability of microRNAs combined with clinical risk models for HCC recurrence post-liver transplantation.
Retrospective analysis including 20 patients with HCC who underwent liver transplantation
MiRNA profiling on formalin-fixed, paraffin-embedded HCC tissue
Evaluation of miRNA expression in conjunction with clinical risk models
Kaplan-Meier analysis to assess recurrence-free survival
Identified a 3-miRNA signature (miR-3692-5p, miR-424, miR-718) that distinguishes between recurrence and non-recurrence
Increased area under the ROC curve from 0.7 to 0.94-0.96 with the addition of miRNA signature to clinical models
High-risk patients had a shorter median recurrence-free survival of 17 months compared to 38.5 months for low-risk patients, p < 0.05

Cite This Study

Lederer et al. (2026) studied this question.

synapsesocial.com/papers/69a288170a974eb0d3c04068 https://doi.org/10.1038/s41598-026-41688-9

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark